Johnson & Johnson (NYSE:JNJ) registered a 1.38% increase, still its new closing price is 16.84% up from the company’s 1 year high of 124.38.It posted -0.67% losses in previous 5 sessions and is now the subject of 14 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 4 buy or better ratings. The 22 stock analysts following this company have an average price target at $124.78, with individual PT in the $108.00-$138.00 range. The shares moved at $113.38, implying that brokerage firms see shares gaining about 14.00% in twelve months time.
Johnson & Johnson (JNJ) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a -1.59% fall year to date. A Director at Johnson & Johnson (JNJ) acquired shares in a transaction closed on Friday October 21, 2016. PRINCE CHARLES bought 875 shares in the company at $114.11 each and collected $99,001 in proceeds. PRINCE CHARLES now owns 27,320 shares in the company after this transaction. A Exec VP, Finance; CFO in the company, Caruso Dominic J, disclosed a transaction on Tuesday July 26, 2016 that ended up generating $5,143,001 from the sale of 41,146 shares at $125.01 per share.
Johnson & Johnson (NYSE:JNJ) Upcoming Results on Tap
Johnson & Johnson will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $1.77 in that period. Sales during the quarter are predicted to arrive at $18.01 billion.
Earnings surprise history: Last quarter, the company posted approximately $18.11 billion in revenue and EPS of $1.58. The mean forecast was for $18.28 billion and $1.56 a share, respectively. One quarter earlier, revenue for the stock was at $17.82 billion, with earnings at $1.68/share.
Johnson & Johnson (JNJ) Brokerage Update
Johnson & Johnson (JNJ) is in Wells Fargo’s research list so their analyst rating change is noteworthy. These shares were downgraded to Market Perform from Outperform by Wells Fargo, according to news reported on Thursday January 26, 2017.Another important research note was issued by Goldman on Monday March 14, 2016.The firm upgraded JNJ to Neutral from Sell. Over the last six months and over the last three months, the shares of Johnson & Johnson (JNJ), have changed -7.66% and -0.35%, respectively.
